Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.41
Ask: 1.43
Change: -0.015 (-1.05%)
Spread: 0.02 (1.418%)
Open: 1.41
High: 1.44
Low: 1.41
Prev. Close: 1.425
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Oct 2020 13:25

RNS Number : 5111D
RTW Venture Fund Limited
28 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

RTW Venture Fund Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: As a result of the recent issuance of new ordinary shares of RTW Venture Fund Limited ("RTW"), Ducasse Group Limited's interest in RTW has been diluted to 9.78% which then triggers the notification threshold.

X

3. Details of person subject to the notification obligationiv

Name

Ducasse Group Limited

City and country of registered office (if applicable)

Road Town, Tortola, British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

Chase Nominees Limited

City and country of registered office (if applicable)

London, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

16/10/2020

6. Date on which issuer notified (DD/MM/YYYY):

28/10/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.78%

N/A

9.78%

187,833,366

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GG00BKTRRM22

18,361,456

9.78%

SUBTOTAL 8. A

18,361,456

9.78%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

The Mountain Trust Company

Mari-Cha Investment Group Limited

Search Private Equity Holdings Limited

Search Private Equity II Limited

Ducasse Group Limited

Chase NomineesLimited

9.78%

N/A

9.78%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Please note, the total amount of voting rights have been rounded to 2 decimal places therefore there is a possibility of a rounding error.

As a result of the recent issuance of new ordinary shares of RTW Venture Fund Limited ("RTW"), Ducasse Group Limited's interest in RTW has been diluted to 9.78% which then triggers the notification threshold.

 

General email contact: fundadminops@sailfunds.com

 

Place of completion

Hong Kong

Date of completion

28/10/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWUORRUURUAA
Date   Source Headline
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics
24th Apr 20232:39 pmRNSMarch Factsheet & First Quarter Letter
17th Apr 20237:00 amRNSPortfolio Company Update: Prometheus Biosciences
17th Apr 20237:00 amRNSMonthly Valuation Update
6th Apr 202312:00 pmRNSAppointment of Numis as Joint Broker
31st Mar 20235:20 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSAnnual Financial Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202310:47 amRNSPortfolio Company Update: Strategic Financing
16th Mar 20234:00 pmRNSDirector Declaration
14th Mar 20237:00 amRNSMonthly Valuation Update
13th Mar 20233:20 pmRNSUpdate re Silicon Valley Bank exposure
1st Mar 20232:45 pmRNSNew Investment in Cargo Therapeutics
1st Mar 202310:00 amRNSNew Investment in Oricell Therapeutics
14th Feb 20237:00 amRNSMonthly Valuation Update
13th Feb 20234:51 pmRNSPortfolio Company Update
26th Jan 202311:32 amRNSQuotedData's Weekly News & Interview
25th Jan 20237:00 amRNSQuarterly Update
20th Jan 20234:29 pmRNSUpdate research from QuotedData
16th Jan 20237:00 amRNSNet Asset Value(s)
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
19th Dec 202211:17 amRNSResult of General Meeting
14th Dec 20227:00 amRNSNet Asset Value(s)
13th Dec 202210:01 amRNSEdison issues flash on RTW Venture Fund (RTW)
8th Dec 20225:57 pmRNSMaterial Update from Portfolio Company
7th Dec 20221:00 pmRNSNew Investment in Apogee Therapeutics
1st Dec 20227:00 amRNSPublication of Circular & Convening of EGM
30th Nov 20222:00 pmRNSDirector/PDMR Shareholding
28th Nov 20227:00 amRNSChange of status for US federal tax - PTP to PFIC
14th Nov 20227:00 amRNSNet Asset Value(s)
4th Nov 20224:04 pmRNSDirector/PDMR Shareholding
1st Nov 20225:07 pmRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSQuarterly Update
20th Oct 20227:00 amRNSEdison issues review on RTW Venture Fund (RTW)
14th Oct 20227:00 amRNSNet Asset Value(s)
22nd Sep 20227:00 amRNSDirector/PDMR Shareholding
16th Sep 20227:00 amRNSPortfolio Company Update: Third Harmonic Bio IPO
15th Sep 20227:30 amRNSNet Asset Value(s)
15th Sep 20227:00 amRNSHalf-year Report
17th Aug 202212:00 pmRNSNotice of Interim Report
12th Aug 20227:00 amRNSNet Asset Value(s)
26th Jul 20227:00 amRNSQuarterly Update
19th Jul 20227:55 amRNSAdditional Investment in Portfolio Company
15th Jul 20227:00 amRNSNet Asset Value(s)
6th Jul 20227:00 amRNSPortfolio Company Transaction Update
21st Jun 20225:33 pmRNSResult of AGM
13th Jun 20227:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.